Holen Sie sich die Stockscreener-App
3.33
6.46%
-0.23
Handel nachbörslich:
3.38
0.05
+1.50%
Schlusskurs vom Vortag:
$3.56
Offen:
$3.5
24-Stunden-Volumen:
534.57K
Relative Volume:
0.06
Marktkapitalisierung:
$22.85M
Einnahmen:
$5.21M
Nettoeinkommen (Verlust:
$-26.35M
KGV:
-0.1038
EPS:
-32.0862
Netto-Cashflow:
$-20.84M
1W Leistung:
+1,452%
1M Leistung:
+1,053%
6M Leistung:
+274.37%
1J Leistung:
+322.00%
1-Tages-Spanne:
$3.25
$3.84
1-Wochen-Bereich:
$0.129
$3.84
52-Wochen-Spanne:
$0.129
$3.84
Plus Therapeutics Inc Stock (PSTV) Company Profile
Firmenname
Plus Therapeutics Inc
Sektor
Branche
Telefon
737.255.7194
Adresse
4200 MARATHON BLVD., AUSTIN, TX
Compare PSTV vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PSTV
Plus Therapeutics Inc
|
3.33 | 24.43M | 5.21M | -26.35M | -20.84M | -32.09 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-03 | Eingeleitet | Lake Street | Buy |
| 2025-09-03 | Hochstufung | D. Boral Capital | Hold → Buy |
| 2025-03-17 | Eingeleitet | D. Boral Capital | Buy |
| 2021-01-25 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2020-10-16 | Eingeleitet | Maxim Group | Buy |
Plus Therapeutics Inc Aktie (PSTV) Neueste Nachrichten
Plus Therapeutics (FRA:XMP1) Shiller PE Ratio : (As of Apr. 05, 2026) - gurufocus.com
Volume Report: Is Plus Therapeutics Inc a top pick in the sectorTrade Exit Summary & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Plus Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | XMP1 | US72941H8060 - marketscreener.com
Plus Therapeutics, Inc.: Target Price Consensus and Analysts Recommendations | XMP1 | US72941H8060 - marketscreener.com
Plus Therapeutics, Inc.: Revenue and Earnings Analysts Forecasts Revisions | XMP1 | US72941H8060 - marketscreener.com
Plus Therapeutics Inc (XMP0.DU) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Plus Therapeutics: Financial Data Forecasts Estimates and Expectations | XMP0 | US72941H8060 - marketscreener.com
Plus Therapeutics: Target Price Consensus and Analysts Recommendations | XMP0 | US72941H8060 - marketscreener.com
Plus Therapeutics Inc (FRA:XMP1) Stock Earnings Transcripts - gurufocus.com
Tranche Update on Plus Therapeutics, Inc.'s Equity Buyback Plan announced on October 31, 2023. - marketscreener.com
Plus Therapeutics: Revenue and Earnings Analysts Forecasts Revisions | XMP0 | US72941H8060 - marketscreener.com
Plus Therapeutics Inc Stock Operating Data - gurufocus.com
Plus Therapeutics Inc (FRA:XMP1) Stock Forecast, Price Targets and Analysts Predictions - gurufocus.com
Plus Therapeutics Inc (FRA:XMP1) Stock Price & 30 Year Financial Data - gurufocus.com
Plus Therapeutics Inc (FRA:XMP1) Stock News, Headlines & Updates - gurufocus.com
Plus Therapeutics Inc (FRA:XMP1) Stock Price, Trades & News - gurufocus.com
Plus Therapeutics: Dividend historical data and projections - marketscreener.com
Plus Therapeutics Enacts Reverse Stock Split to Maintain Listing - TipRanks
Reverse split shrinks Plus Therapeutics (NASDAQ: PSTV) share count to 6.9M - Stock Titan
Plus Therapeutics (NASDAQ:PSTV) Stock Price Down 9.9%Here's Why - MarketBeat
Plus Therapeutics Expands Reimbursement for CNSide® CSF Assay to 75 Million Covered Lives - National Today
Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives - manilatimes.net
PSTV Stock Chart | PLUS THERAPEUTICS INC (NASDAQ:PSTV) - ChartMill
Plus Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Sims Andrew John Hugh MacIntyremoomoo - Moomoo
Plus Therapeutics (PSTV) CFO acquires 67,452 shares through RSU vesting - Stock Titan
Plus Therapeutics (PSTV) CEO exercises 361,313 RSUs into stock - Stock Titan
Plus Therapeutics Inc. (NASDAQ:PSTV) - intelligentinvestor.com.au
Plus Therapeutics approves 1-for-25 reverse stock split By Investing.com - Investing.com Australia
Plus Therapeutics, Inc. Announces 1-for-25 Reverse Stock Split Effective April 2, 2026 - Moomoo
Plus Therapeutics | DEF 14A: Definitive information statements - moomoo.com
Published on: 2026-04-01 11:00:22 - baoquankhu1.vn
Plus Therapeutics To Carry Out 1-for-25 Reverse Stock Split On April 2nd, 2026 - Moomoo
Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Bitget
Plus Therapeutics Approves 1-for-25 Reverse Stock Split - Intellectia AI
[ARS] PLUS THERAPEUTICS, INC. SEC Filing - Stock Titan
Plus Therapeutics (NASDAQ: PSTV) sets 2026 virtual meeting, executive pay and equity plan vote - Stock Titan
Plus Therapeutics announces 1-for-25 reverse stock split - MSN
This Rockwell Automation Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For TuesdayCentessa P - Benzinga
Plus Therapeutics (PSTV) Downgraded to Hold by D. Boral Capital - gurufocus.com
Plus Therapeutics Announces Reverse Stock Split - Bitget
D. Boral Capital downgrades Plus Therapeutics stock rating on reverse split By Investing.com - Investing.com South Africa
D. Boral Capital downgrades Plus Therapeutics stock rating on reverse split - investing.com
Plus Therapeutics approves 1-for-25 reverse stock split - investing.com
Plus Therapeutics announces reverse stock split - MarketScreener
PLUS THERAPEUTICS (PSTV) director files Form 3 with zero shares - Stock Titan
PSTV Stock Price, Quote & Chart | PLUS THERAPEUTICS INC (NASDAQ:PSTV) - ChartMill
PLUS THERAPEUTICS, INC. Files Form 8-K Current Report with SEC – Company Details, Address, and Compliance Information 18 - Minichart
Plus Therapeutics Appoints Ron Andrews to Board - Intellectia AI
Plus Therapeutics appoints Ronald A. Andrews to board following director resignation By Investing.com - Investing.com South Africa
Plus Therapeutics Adds Industry Veteran Ronald Andrews to Board - TipRanks
Plus Therapeutics appoints Ronald A. Andrews to board following director resignation - Investing.com
Finanzdaten der Plus Therapeutics Inc-Aktie (PSTV)
Umsatz
Nettogewinn
Free Cashflow
ENV
Plus Therapeutics Inc-Aktie (PSTV) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| HEDRICK MARC H | Chief Executive Officer |
Apr 01 '26 |
Option Exercise |
0.00 |
159,681 |
0 |
499,468 |
| HEDRICK MARC H | Chief Executive Officer |
Jan 01 '26 |
Option Exercise |
0.00 |
159,681 |
0 |
339,787 |
| Sims Andrew John Hugh MacIntyr | Chief Financial Officer |
Jan 01 '26 |
Option Exercise |
0.00 |
38,323 |
0 |
106,461 |
| Sims Andrew John Hugh MacIntyr | Chief Financial Officer |
Nov 04 '25 |
Buy |
0.51 |
20,000 |
10,200 |
68,138 |
| HEDRICK MARC H | Chief Executive Officer |
Oct 01 '25 |
Option Exercise |
0.00 |
159,681 |
0 |
180,106 |
| Sims Andrew John Hugh MacIntyr | Chief Financial Officer |
Oct 01 '25 |
Option Exercise |
0.00 |
38,323 |
0 |
48,138 |
| Lenk Robert P | Director |
Aug 22 '25 |
Buy |
0.49 |
110,000 |
53,779 |
139,327 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):